Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0SR4G
|
||||
| Former ID |
DIB005924
|
||||
| Drug Name |
ONT-093
|
||||
| Synonyms |
MDR inhibitors, Ontogen; OC-144-093
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Discontinued in Phase 1 | [1] | ||
| Company |
Ontogen Corp
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C32H38N4O
|
||||
| Canonical SMILES |
n1c(c([nH]c1c1ccc(/C=C/COCC)cc1)c1ccc(NC(C)C)cc1)c1ccc(<br />NC(C)C)cc1
|
||||
| CAS Number |
CAS 216227-54-2
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Multidrug resistance protein 1 | Target Info | Inhibitor | [2] | |
| KEGG Pathway | ABC transporters | ||||
| Bile secretion | |||||
| MicroRNAs in cancer | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| TCR Signaling Pathway | |||||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | ||||
| Reactome | ABC-family proteins mediated transport | ||||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Abacavir transport and metabolism | |||||
| Multi Drug Resistance Protein 1 (Glycoprotein 1) Regulation | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Allograft Rejection | |||||
| Drug Induction of Bile Acid Pathway | |||||
| Codeine and Morphine Metabolism | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011621) | ||||
| REF 2 | A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005 Aug;23(4):311-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.